Pegloticase in conjunction with immunomodulator combination therapy significantly increased pegloticase responder rates when compared with pegloticase monotherapy for patients with uncontrolled or refractory gout, according to a study. This week, Rheumatology Network interviewed lead investigator, Robert Keenan, MD, to discuss his findings.
Brian Skaggs, PhD, and Maureen McMahon, MD, sat down with Rheumatology Network to discuss the results of their longitudinal study, “A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.”
Rheumatology Network sat down with Liana Fraenkel, MD, MPH, the lead investigator for the study: OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies. In partnership with CreakyJoints, Fraenkel is a rheumatologist at Berkshire Medical Center and Director of Patient Centered Population Health Research.
Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss his 2 most recent studies. Nowell is the Director of Patient-Centered Research at CreakyJoints, part of the Global Healthy Living Foundation.
Rheumatology Network sat down for an interview with Glenn Haugeberg, MD, PhD, from Sørlandet Hospital, in Norway, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He will be presenting his findings on Biosimilars: Review and Real-World Experience and Osteoimmunology: Osteoporosis and Beyond.
Rheumatology Network interviewed Roy Fleischmann, MD, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He is presenting his findings on Combination Therapy in Rheumatology and Rheumatology 2020: A Year in Review of Novel Therapies.
This week we sat down for an interview with Arthur Kavanaugh, MD, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He is currently the chairman for the 2021 conference. Kavanaugh is Professor of Medicine and Director of the Center for Innovative Therapy at UC San Diego. He will be presenting his findings on Rheumatology 2020: A Year in Review for rheumatoid arthritis, spondylarthritis, and psoriatic arthritis. We discuss what sets RWCS apart from other conferences and the exciting content that participants can expect.
This week, we sat down for an interview with Alice Fike, MS, NP, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to discuss her study titled “Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients.” The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by coronavirus disease 2019 (COVID-19).
This week, we sat down for an interview with April Jorge, MD, to discuss the findings of her study, “Temporal trends and severe COVID-19 outcomes in patients with rheumatic disease,” and what this may mean for patients with rheumatic disease moving forward in the pandemic.
Puja Khanna MD, MPH, associate professor of medicine at the University of Michigan, discusses a presentation she gave at the American College of Rheumatology Convergence 2020 on reducing the immunogenicity of pegloticase and improving its efficacy.
In today's interview, our focus is on patient perspectives. During the American College of Rheumatology annual meeting last month, Juana Mata shared her story of a life living with lupus. Getting an accurate diagnosis wasn't easy, but eventually she found a doctor and treatment that's working for her. In today's interview, Kim Gorgens, a psychologist and Rheumatology Network board member interviews Juana and her sister, Estela, who describe turning a lupus diagnosis into a positive force for change through advocacy. The sisters have created a non-profit group called Looms for Lupus in which they embrace art therapy to relieve stress.
In rheumatoid arthritis, physician scientists are beginning to zero in on personalized medicine. In this interview, Dr. Leslie R. Harrold, chief scientific officer of Corrona, and a University of Massachusetts associate professor, summarizes a study she recently presented at ACR 2020 in which she describes biomarkers and patient characteristics she and her team have identified as taking us one step closer to precision medicine.
